Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis

Trends in Endocrinology and Metabolism

Volumn 13, Issue 8, 2002, Pages 331-335

  Lee, Chih Hao ^a   Evans, Ronald M ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CORONARY ARTERY; FEMALE; FOAM CELL; HOMEOSTASIS; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; TARGET ORGAN; ANIMAL; ARTERIOSCLEROSIS; DISEASE MODEL; DRUG POTENTIATION; HUMAN; LIPID METABOLISM; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; HOMEOSTASIS; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGES; MICE; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036781460     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(02)00668-9     Document Type: Review

References (48)

1. Chawla, A. et al. (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870
2. Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688
3. Kliewer, S.A. et al. (2001) Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 56, 239-263
4. Dreyer, C. et al. (1993) Positive regulation of the peroxisomal P-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell 77, 67-76
5. Forman, B.M. et al. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317
6. Kliewer, S.A. et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. U. S.A. 94, 4318-4323
7. Krey, G. et al. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11, 779-791
8. Forman, B.M. et al. (1995) 15-Deoxy-δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803-812
9. Kliewer, S.A. et al. (1995)A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813-819
10. Lehmann, J.M. et al. (1995)An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPARγ). J. Biol. Chem. 270, 12953-12956
11. Barak, Y. et al. (1999) PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595
12. Kubota, N. et al. (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609
13. Rosen, E.D. et al. (1999) PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611-617
14. Peters, J.M. et al. (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptorβ (δ). Mol. Cell. Biol. 20, 5119-5128
15. Michalik, L. et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) α- and PPARβ-mutant mice. J. Cell Biol. 154, 799-814
16. Oliver, W.R., Jr et al. (2001) A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98, 5306-5311
17. Tontonoz, P. et al. (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252
18. Nagy, L. et al. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93, 229-240
19. Ricote, M. et al. (1998) The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 391, 79-82
20. Jiang, C. et al. (1998) PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86
21. Spiegelman, B.M. (1998) PPARγ adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514
22. Staal, F.J. and Clevers, H.C. (2001) Regulation of lineage commitment during lymphocyte development. Int. Rev. Immunol. 20, 45-64
23. Nagamura-Inoue, T. et al. (2001) Transcription factors that regulate growth and differentiation of myeloid cells. Int. Rev. Immunol. 20, 83-105
24. Lin, R.J. et al. (2001) Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20, 7204-7215
25. Chawla, A. et al. (2001) PPARγ-dependent and -independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7, 48-52
26. Moore, K.J. et al. (2001) The role of PPARγ in macrophage differentiation and cholesterol uptake. Nat. Med. 7, 41-47
27. Lusis, A.J. (2000) Atherosclerosis. Nature 407, 233-241
28. Glass, C.K. and Witztum, J.L. (2001) Atherosclerosis. The road ahead. Cell 104, 503-516
29. Plutzky, J. (2001) Peroxisome proliferator-activated receptors in endothelial cell biology. Curr. Opin. Lipidol. 12, 511-518
30. Yang, X.Y. et al. (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J. Biol. Chem. 275, 4541-4544
31. Thieringer, R. et al. (2000) Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo. J. Immunol. 164, 1046-1054
32. Castrillo, A. et al. (2000) Inhibition of IκB kinase and IκB phosphorylation by 15-deoxy- δ(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20, 1692-1698
33. Rossi et al. (2000)Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103-108
34. Li, M. et al. (2000) Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20, 4699-4707
35. Suzuki, H. et al. (1997) The multiple roles of macrophage scavenger receptors (MSR) in vivo: resistance to atherosclerosis and insusceptibility to infection in Msr-knockout mice. J. Atheroscler. Thromb 4, 1-11
36. Febbraio, M. et al. (2000) Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105, 1049-1056
37. Chinetti, G. et al. (2001) PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7, 53-58
38. Chawla, A. et al. (2001) A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7, 161-171
39. Repa, J.J. et al. (2000) Regulation of absorption andABC 1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529
40. Venkateswaran, A. et al. (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc. Natl. Acad. Sci. U. S. A. 97, 12097-12102
41. Costet, P. et al. (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275, 28240-28245
42. Schmitz, G. and Langmann, T. (2001) Structure, function and regulation of the ABC1 gene product. Curr. Opin. Lipidol. 12, 129-140
43. Reardon, C.A. and Getz, G.S. (2001) Mouse models of atherosclerosis. Curr. Opin. Lipidol. 12, 167-173
44. Li, A.C. et al. (2000) Peroxisome proliferator-activated receptor 7 ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106, 523-531
45. Collins, A. R. et al. (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 365-371
46. Chen, Z. et al. (2001) Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21, 372-377
47. Claudel, T. et al. (2001) Reduction of atherosclerosis in apolipoprotein E-knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. U. S. A. 98, 2610-2615
48. Laffitte, B. A. et al. (2001) Autoregulation of the human liver X receptor α promoter. Mol. Cell. Biol. 21, 7558-7568